H. Lundbeck A/S (0ND5.IL)

33,46 -0,09 (-0,28%) In data: 03:54PM BST. Mercato aperto.

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 5.600

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Joerg Hornstein	CFO & Exec. VP of Corp. Functions	3,4M	N/D	1977
Mr. Jacob Tolstrup	Exec. VP of Commercial Operations	8,2M	N/D	1972
Mr. Lars Bang	Exec. VP of Product Devel. & Supply	7,7M	N/D	1962
Dr. Per Johan Luthman	Exec. VP of R&D	8,6M	N/D	1959
Mr. Charl van Zyl	Pres & CEO	N/D	N/D	1967
Dr. Tarek Samad Ph.D.	Sr. VP & Head of Research	N/D	N/D	N/D
Mr. Palle Holm Olesen	Chief Specialist & VP of Investor Relations	N/D	N/D	N/D
Ms. Elise Hauge	Exec. VP of People & Communication	N/D	N/D	1967
Mr. Ole Chrintz	Sr. VP of International Markets	N/D	N/D	1958
Mr. Keld Flintholm Jorgensen	Exec. VP of Corp. Strategy & Bus. Devel.	N/D	N/D	1971

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Governance aziendale

L'ISS Governance QualityScore di H. Lundbeck A/S al 1 ottobre 2023 è 2. I criteri di valutazione fondamentali sono revisione: 4; Consiglio di Amministrazione: 3; diritti degli azionisti: 9; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.